XTX Topco Ltd Takes Position in LifeMD, Inc. (NASDAQ:LFMD)

XTX Topco Ltd bought a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,701 shares of the company’s stock, valued at approximately $94,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in LFMD. Quest Partners LLC acquired a new stake in shares of LifeMD during the 2nd quarter worth approximately $31,000. Los Angeles Capital Management LLC acquired a new stake in LifeMD in the 2nd quarter valued at $88,000. EntryPoint Capital LLC bought a new position in shares of LifeMD during the first quarter valued at $89,000. Virtu Financial LLC bought a new stake in shares of LifeMD in the 1st quarter worth about $249,000. Finally, Rhumbline Advisers acquired a new position in LifeMD in the second quarter valued at about $326,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Trading Down 3.2 %

NASDAQ:LFMD opened at $5.07 on Wednesday. The firm has a market capitalization of $211.71 million, a price-to-earnings ratio of -6.85 and a beta of 1.19. LifeMD, Inc. has a 1-year low of $4.65 and a 1-year high of $12.88. The business’s 50-day moving average price is $5.48 and its two-hundred day moving average price is $7.65. The company has a current ratio of 0.87, a quick ratio of 0.83 and a debt-to-equity ratio of 10.83.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $50.66 million for the quarter, compared to analyst estimates of $48.47 million. During the same quarter last year, the firm earned ($0.23) earnings per share. On average, equities analysts expect that LifeMD, Inc. will post -0.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LFMD. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. B. Riley began coverage on LifeMD in a research report on Friday, August 23rd. They set a “buy” rating and a $11.00 target price for the company. Finally, KeyCorp lowered their price objective on LifeMD from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.